Short Interest in Rezolute, Inc. (NASDAQ:RZLT) Decreases By 16.7%

Rezolute, Inc. (NASDAQ:RZLT) was the recipient of a large decline in short interest in the month of September. As of September 15th, there was short interest totalling 1,050,000 shares, a decline of 16.7% from the August 31st total of 1,260,000 shares. Based on an average trading volume of 325,100 shares, the short-interest ratio is currently 3.2 days.

Analysts Set New Price Targets

Several equities analysts recently commented on the company. JMP Securities reiterated a “market outperform” rating and issued a $7.00 target price on shares of Rezolute in a research note on Friday, September 20th. Maxim Group upped their price objective on shares of Rezolute from $8.00 to $10.00 and gave the company a “buy” rating in a research note on Tuesday, August 6th. Craig Hallum assumed coverage on shares of Rezolute in a research report on Tuesday, June 4th. They issued a “buy” rating and a $14.00 target price on the stock. HC Wainwright restated a “buy” rating and issued a $14.00 target price on shares of Rezolute in a report on Friday. Finally, Guggenheim initiated coverage on shares of Rezolute in a research note on Tuesday, August 27th. They set a “buy” rating and a $11.00 price target on the stock. Seven research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $11.57.

Institutional Investors Weigh In On Rezolute

Hedge funds have recently modified their holdings of the stock. Vanguard Group Inc. boosted its holdings in Rezolute by 10.4% in the 1st quarter. Vanguard Group Inc. now owns 1,553,352 shares of the company’s stock worth $3,961,000 after acquiring an additional 145,700 shares during the period. Affinity Asset Advisors LLC lifted its position in shares of Rezolute by 15.6% during the second quarter. Affinity Asset Advisors LLC now owns 1,850,000 shares of the company’s stock worth $7,955,000 after purchasing an additional 250,000 shares in the last quarter. Virtu Financial LLC purchased a new position in shares of Rezolute in the first quarter valued at $37,000. Acadian Asset Management LLC acquired a new stake in Rezolute during the 1st quarter valued at $229,000. Finally, Federated Hermes Inc. increased its stake in Rezolute by 11.1% during the 2nd quarter. Federated Hermes Inc. now owns 11,279,327 shares of the company’s stock worth $48,501,000 after buying an additional 1,125,000 shares during the period. 82.97% of the stock is currently owned by hedge funds and other institutional investors.

Rezolute Price Performance

RZLT stock traded up $0.10 during midday trading on Friday, reaching $4.98. 161,171 shares of the company’s stock traded hands, compared to its average volume of 437,974. The business has a 50-day moving average price of $4.64 and a two-hundred day moving average price of $3.82. Rezolute has a fifty-two week low of $0.72 and a fifty-two week high of $6.10. The company has a market capitalization of $199.87 million, a P/E ratio of -4.37 and a beta of 1.18.

Rezolute (NASDAQ:RZLT) last announced its quarterly earnings results on Thursday, September 19th. The company reported ($0.44) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.30) by ($0.14). As a group, research analysts forecast that Rezolute will post -1.38 earnings per share for the current fiscal year.

About Rezolute

Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.